Are young infants treated with erythromycin at risk for developing hypertrophic pyloric stenosis?
Date First Published:
March 6, 2007
Last Updated:
March 6, 2007
Report by:
Nitin Maheshwai, Specialist Registrar in Paediatrics (Oxford Deanery)
Search checked by:
Bob Phillips, Oxford Deanery
Three-Part Question:
Are the [young infants] [exposed to erythromycin] [at risk for developing hypertrophic pyloric stenosis]?
Clinical Scenario:
A 5-week-old infant is admitted to a high dependency unit with paroxysmal cough associated with dusky episodes. The severity and frequency of cough paroxysm increases and 48 h later pernasal swab confirms the diagnosis of pertusis. You want to treat the infant with erythromycin. However, you have heard that erythromycin can cause hypertrophic pyloric stenosis in young infants. So you decide to find out more before starting the treatment.
Search Strategy:
Medline (1951–2006) via Dialog DATA star:
Search Details:
Keywords: erythromycin or maciolides AND pyloric stenosis or infantile hypertrophic pyloric stenosis.
Limits: Human and English
Embase and Pubmed: Same search strategy used. No further relevant papers found.
Cochrane Database and Bestbets website: No further papers found.
Limits: Human and English
Embase and Pubmed: Same search strategy used. No further relevant papers found.
Cochrane Database and Bestbets website: No further papers found.
Outcome:
A total of 30 articles were found. All the abstracts were read and six relevant articles were identified for the analysis (table).
One systematic review included in the analysis was primarily designed to look at the use of erythromycin as a prokinetic agent in preterm infants (Patole). Another systemic review (Ng) looking at the use of erythromycin for the same was read but not included in the analysis. This review included only two studies. One of those was included in the other systemic review, analysed here, and the second study was published only in abstract form, and the possible association between erythromycin and pyloric stenosis was not discussed. Three other relevant case reports (Stang,Yuhko, Wimol) were read but not included in the analysis because of small sample sizes in all of them.
One systematic review included in the analysis was primarily designed to look at the use of erythromycin as a prokinetic agent in preterm infants (Patole). Another systemic review (Ng) looking at the use of erythromycin for the same was read but not included in the analysis. This review included only two studies. One of those was included in the other systemic review, analysed here, and the second study was published only in abstract form, and the possible association between erythromycin and pyloric stenosis was not discussed. Three other relevant case reports (Stang,Yuhko, Wimol) were read but not included in the analysis because of small sample sizes in all of them.
Relevant Paper(s):
| Study Title | Patient Group | Study type (level of evidence) | Outcomes | Key results | Study Weaknesses |
|---|---|---|---|---|---|
| Infantile hypertrophic pyloric stenosis related to ingestion of erythromycin estolate: a report of five cases. SanFillippo JA. 1976, USA | 963 live births at Naval Hospital, Great Lakes, between November 1972 and October 1973. All the infants with confirmed pyloric stenosis during this period were identified | Retrospective cohort study (level IIb) | Association between erythromycin use and development of pyloric stenosis | Five of six infants with operative confirmed pyloric stenosis received erythromycin estolate at a dose of 40 mg/kg/day for superficial skin infections between 8 and 17 days of life | Small sample size Retrospective study No controls Detailed discussion of all the cases was reported No specific information was given on the prevalence of erythromycin use among infants who did not develop IHPS |
| Infantile hypertrophic pyloric stenosis after pertusis prophylaxis with erythromycin: a case review and cohort study. Honein MA, Paulozzi LJ, Himelright IM, et al. 1999, USA | 282 infants born in Jan– Feb 1999 at a community hospital | Retrospective cohort study and case review (level IIb) 157 of those were given erythromycin as post pertusis exposure prophylaxis whereas 125 were not given erythromycin |
Association between erythromycin use and development of pyloric stenosis | Absolute risk of IHPS was 5.1% for infants who took erythromycin for 8–14 days and 10% for infants who took it for 15–21 days<br><br>Risk did not differ by erythromycin preparation (ethylsuccinate or estolate)<br><br>The seven index cases were younger at the time erythromycin started (median 5 days) than the unaffected infants exposed to erythromycin (median 13 days, mean 14.1 days) | A blinded independent review of ultrasonography scans of the seven IHPS cases identified at surgery, and seven negative ultrasonography scans of the pylorus from the same hospital during the same period was obtained to validate the diagnosis. All of the seven index cases with IHPS were compared with historical IHPS cases at the two hospitals in the region at which pyloromyotomies were performed |
| Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. Mahon BE, Rosenman MB, Kleiman MB. 2001, USA | 14 876 Infants born at an urban hospital from June 1993 through December 1999. Infants who died in first 3 months of life and infants who did not receive care within the study network were excluded from the study. A total of 469 infants were prescribed systemic erythromycin, 124 erythromycin ophthalmic ointment and 3346 mothers were prescribed systemic erythromycin | Retrospective cohort (level IIb) | Association between erythromycin use and development of pyloric stenosis | Infants who were prescribed systemic erythromycin had increased risk of IHPS with the highest risk in the first 2 weeks of life (relative risk = 10.51, 95% CI 4.48 to 24.66)<br><br>Prescriptions of longer periods of treatment (>14 days) were associated with higher risk (p<0.05). Erythromycin ophthalmic ointment use was not associated with increased risk of IHPS<br><br>There were inconclusive data related to the association between maternal use of macrolides within 10 weeks of delivery and IHPS | Retrospective study Decent sample size No specific information was obtained to assess the compliance with the treatment |
| Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Cooper WO, Griffin MR, Arbogast P, et al. 2002, USA | Medicaid or TennCare (Tennessee's program for Medicaid enrolees and uninsured individuals) births in Tennessee from 1985 to 1997 (314 029 infants) All the infants with a diagnosis of pylorics stenosis at hospital discharge and an associated surgical procedure were identified. Exposure to erythromycin or other antibiotics between 3 and 90 days of life was identified from prescription files Among 314 029 infants enrolled in Medicaid, 804 (2.6/100 infants) met the criteria for pyloric stenosis |
Retrospective cohort study (level IIb) | Association between erythromycin use and development of pyloric stenosis | Very early exposure to erythromycin (between 3 and 13 days of life) was associated with nearly eightfold increased risk of pyloric stenosis (adjusted incidence rate, 7.88; 95% CI 1.97 to 31.57)<br><br>Exposure to erythromycin before 90 days of life was associated with a twofold increase risk of pyloric stenosis (adjusted rate ratio, 2.05; 95% CI 1.06 to 3.97). No increased risk of pyloric stenosis was seen in infants exposed to antibiotics other than erythromycin. | Retrospective study Decent sample size Infants included in Honein et al's study were not included |
| Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolids. Sorensen HT, Skriver MV, Pedersen L, et al. 2003, Denmark | All women who had live or still births after 28 weeks of gestation between 1991 and 2000 in the Danish county of North Jutland Data on drug exposure and IHPS on all of them was obtained from National Health Service, Danish Birth Registry and hospital discharge registry A total of 1166 pregnant women were prescribed macrolides from birth to 90 days postnatally. 41 778 women who were not prescribed erythromycin acted as control |
Population-based cohort study (level IIb) | Association between erythromycin use and development of pyloric stenosis | The use of macrolides during breast feeding increases the risk of IHPS<br><br>The odds ratio for IHPS varied between 2.3 and 3 according to different periods of postnatal exposure, and after stratification for sex, they were 10.3 (95% CI 1.2 – 92.3) for girls and 2.0 (95% CI 0.5 –8.4) for boys. | No specific information was obtained to assess compliance with treatment Insufficient power Discharge diagnosis in the database used in the study are not entirely accurate, the proportion of misclassified cases in the used database is 5–15%. |
| Erythromycin as a prokinetic agent in preterm neonates: a systemic review. Patole S, Rao S, Doherty D. 2005, Australia | A total of seven studies looking at the use of erythromycin as a prokinetic agent in preterm neonates involving 359 preterm neonates (<37 weeks). | Systemic review (level Ia) | Primary outcome: time taken to reach full enteral feeds. Secondary outcome: Erythromycin-related adverse side effects such as hypertrophic pyloric stenosis | The issue of erythromycin-related adverse effects cannot be considered adequately given the small sample size and insufficient data on long-term follow-up<br><br>None of the infants from available data developed hypertrophic pyloric stenosis | In three of the seven studies, erythromycin was used at a higher dose (>12 mg/kg/6–8 h). In the remaining four studies, it was used at a low dose (3–12 mg/kg/day). |
Author Commentary:
Infantile hypertrophic pyloric stenosis is a condition of early infancy in which hypertrophy of pylorus results in gastric outlet obstruction. The aetiology of this condition remains unclear. Genetic predisposition acting in conjunction with environmental factors is the most widely accepted explanation.
Erythromycin is a motilin receptor agonist. It has been hypothesised that erythromycin interacts with motilin receptors, inducing strong gastric and pyloric bulb contractions and resulting in pylorus hypertrophy (Peeters, Jadcherla). Thus, it is plausible that young infants treated with erythromycin may be at increased risk for developing hypertrophic pyloric stenosis. Four cohort studies (table) were found that dealt with this possible causal association. All of them were retrospective and had methodological flaws, but unanimously suggested that young infants treated with a high, antimicrobial dose of erythromycin (about 40 mg/kg/day) are at risk for developing hypertrophic pyloric stenosis. The risk was reported to be substantially higher (8–10-fold) in the first 2 weeks of life in term or near-term infants and did not differ by erythromycin preparations (ethylsuccinate or estolate). Infants treated with erythromycin for longer durations (>14 days) were found to be at higher risk than those treated for shorter durations.
Erythromycin is excreted into breast milk, and the level of erythromycin in breast milk is 50–100% of the level in maternal plasma (Briggs). So it would not be unreasonable to suspect that maternal use of macrolides during breast feeding may also increase the risk of infantile hypertrophic pyloric stenosis. A large population-based cohort study (Sorenson) was found dealing with this question and suggested that the use of macrolides during breast feeding increases the risk of infantile hypertrophic pyloric stenosis.
Newer macrolides, such as azithromycin, have recently become popular among clinicians because of the shorter duration of treatment and fewer gastrointestinal side effects than erythromycin. Only a small number of infants treated with azithromycin after the first 6 weeks of life were included in the study by Mahon et al. None of them developed pyloric stenosis. In another study,(Friedman) primarily designed to look at efficacy of azithromycin as a post-pertusis exposure chemoprophylactic agent, 58 neonates were given azithromycin. None of them developed pyloric stenosis. Further evidence is required before a definite conclusion can be drawn regarding the use of newer macrolides and subsequent development of pyloric stenosis.
Erythromycin is used in preterm babies with feed intolerance in some centres. A systematic review (Patole) looking at the use of erythromycin as a prokinetic agent failed to consider the issue of erythromycin-related side effects, including pyloric stenosis adequately, given the small sample size and insufficient data on long-term follow-up in the included studies.
At this stage, on the basis of published evidence, it can be concluded that young infants exposed to erythromycin in the first few weeks of life are at greater risk for developing hypertrophic pyloric stenosis. The highest risk seems to be in the first 2 weeks of life in term or near-term infants, and with courses of >14 days. Infants exposed to erythromycin through breast milk may be at risk for developing hypertrophic pyloric stenosis, although further evidence is required to confirm this causal association.
Erythromycin should only be used in young infants (<4 weeks) when the therapeutic benefits outweigh the risks and no alternative agent is available
Erythromycin is a motilin receptor agonist. It has been hypothesised that erythromycin interacts with motilin receptors, inducing strong gastric and pyloric bulb contractions and resulting in pylorus hypertrophy (Peeters, Jadcherla). Thus, it is plausible that young infants treated with erythromycin may be at increased risk for developing hypertrophic pyloric stenosis. Four cohort studies (table) were found that dealt with this possible causal association. All of them were retrospective and had methodological flaws, but unanimously suggested that young infants treated with a high, antimicrobial dose of erythromycin (about 40 mg/kg/day) are at risk for developing hypertrophic pyloric stenosis. The risk was reported to be substantially higher (8–10-fold) in the first 2 weeks of life in term or near-term infants and did not differ by erythromycin preparations (ethylsuccinate or estolate). Infants treated with erythromycin for longer durations (>14 days) were found to be at higher risk than those treated for shorter durations.
Erythromycin is excreted into breast milk, and the level of erythromycin in breast milk is 50–100% of the level in maternal plasma (Briggs). So it would not be unreasonable to suspect that maternal use of macrolides during breast feeding may also increase the risk of infantile hypertrophic pyloric stenosis. A large population-based cohort study (Sorenson) was found dealing with this question and suggested that the use of macrolides during breast feeding increases the risk of infantile hypertrophic pyloric stenosis.
Newer macrolides, such as azithromycin, have recently become popular among clinicians because of the shorter duration of treatment and fewer gastrointestinal side effects than erythromycin. Only a small number of infants treated with azithromycin after the first 6 weeks of life were included in the study by Mahon et al. None of them developed pyloric stenosis. In another study,(Friedman) primarily designed to look at efficacy of azithromycin as a post-pertusis exposure chemoprophylactic agent, 58 neonates were given azithromycin. None of them developed pyloric stenosis. Further evidence is required before a definite conclusion can be drawn regarding the use of newer macrolides and subsequent development of pyloric stenosis.
Erythromycin is used in preterm babies with feed intolerance in some centres. A systematic review (Patole) looking at the use of erythromycin as a prokinetic agent failed to consider the issue of erythromycin-related side effects, including pyloric stenosis adequately, given the small sample size and insufficient data on long-term follow-up in the included studies.
At this stage, on the basis of published evidence, it can be concluded that young infants exposed to erythromycin in the first few weeks of life are at greater risk for developing hypertrophic pyloric stenosis. The highest risk seems to be in the first 2 weeks of life in term or near-term infants, and with courses of >14 days. Infants exposed to erythromycin through breast milk may be at risk for developing hypertrophic pyloric stenosis, although further evidence is required to confirm this causal association.
Erythromycin should only be used in young infants (<4 weeks) when the therapeutic benefits outweigh the risks and no alternative agent is available
Bottom Line:
Infants exposed to therapeutic doses of erythromycin in the first few weeks of life are at greater risk for developing hypertrophic pyloric stenosis (grade B).
The highest risk seems to be in the first 2 weeks of life in term or near-term infants, and with courses of >14 days (grade B).
Erythromycin given for feed intolerance is not clearly associated with HPS (grade D).
The highest risk seems to be in the first 2 weeks of life in term or near-term infants, and with courses of >14 days (grade B).
Erythromycin given for feed intolerance is not clearly associated with HPS (grade D).
References:
- SanFillippo JA.. Infantile hypertrophic pyloric stenosis related to ingestion of erythromycin estolate: a report of five cases.
- Honein MA, Paulozzi LJ, Himelright IM, et al.. Infantile hypertrophic pyloric stenosis after pertusis prophylaxis with erythromycin: a case review and cohort study.
- Mahon BE, Rosenman MB, Kleiman MB.. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis.
- Cooper WO, Griffin MR, Arbogast P, et al.. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis.
- Sorensen HT, Skriver MV, Pedersen L, et al.. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolids.
- Patole S, Rao S, Doherty D.. Erythromycin as a prokinetic agent in preterm neonates: a systemic review.
- Ng E, Shah V.. Erythromycin for feeding intolerance in preterm infants.
- Stang H.. Pyloric stenosis associated with erythromycin ingested through breast milk.
- Yuhko S, Hirokazu T, Ritsuyo K, et al.. Erythromycin in ELBW infants.
- Wimol S, Nuntnarumit P, et al.. Oral erythromycin for treatment of feeding intolerance in preterm infants: a preliminary report.
- Peeters T, Matthijs G, Depoortere I, et al.. Eryhtromycin is a motilin receptor agonist.
- Jadcherla S, Kleg G, Berseth C.. Regulation of migrating motor complexes by motilin and pancreatic polupeptide in human infants.
- Briggs GG, Freeman RK, Yaffe SJ.. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk.
- Friedman DS, Curtis RC, Schauer SL, et al.. Surveillance for transmission and antibiotic adverse events among neonates and adults exposed to a healthcare worker with pertussis.